| Market Capitalization (Millions $) |
2,157 |
| Shares
Outstanding (Millions) |
38 |
| Employees |
92 |
| Revenues (TTM) (Millions $) |
32 |
| Net Income (TTM) (Millions $) |
-182 |
| Cash Flow (TTM) (Millions $) |
243 |
| Capital Exp. (TTM) (Millions $) |
2 |
Keros Therapeutics Inc
Keros Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for rare genetic diseases characterized by a deficiency in specific proteins. Keros Therapeutics was founded in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics is primarily focused on developing small molecule therapeutics that can modulate the activity of protein targets known to play a critical role in human disease. The company's lead drug candidate, KER-050, is a potent and selective agonist of the erythropoietin receptor (EPOR). The EPOR is a crucial protein involved in the regulation of red blood cell production and survival. KER-050 is currently being evaluated in a Phase 2 clinical trial for treatment for patients with myelodysplastic syndromes (MDS) or myelofibrosis (MF) who are anemic and require red blood cell transfusions.
Keros Therapeutics' pipeline also includes several other drug candidates targeting various disease indications. These include KER-047, a small molecule inhibitor of secretion and TGF-e activation, which is being developed for treatment of fibrotic diseases; KER-012, a small molecule Modulator of the Transforming Growth Factor Beta (TGF-e) Pathway, which is being developed for the treatment of certain fibrotic disorders and cancer; and KER-044, a small molecule activator of a protein that can enhance glucose uptake which is being developed for treatment of certain metabolic disorders, including Type 2 diabetes.
Keros Therapeutics is committed to leveraging its expertise in drug discovery and development to bring novel therapies to patients with unmet medical needs. To this end, the company employs cutting-edge technologies in protein engineering, structural biology, and computer-aided drug design to identify and optimize potential drug candidates. Keros has also established partnerships with academic and industry collaborators to expand its drug discovery capabilities and further augment its pipeline.
The company has a strong management team that includes experienced leaders from the biotech and pharmaceutical industries. Keros Therapeutics' CEO, Jasbir Seehra, has over 25 years of experience in biotech drug discovery and has previously served in leadership roles at Genentech, Inc. and Amgen Inc. The company's scientific co-founders, Drs. Avrum Spira and Benjamin Ebert, are both leading experts in their respective fields of genomics and hematology and have made significant contributions to academic research in these areas.
Overall, Keros Therapeutics is a promising biopharmaceutical company that is focused on developing novel drugs to treat rare genetic diseases where there are limited treatment options. With an experienced management team, promising pipeline, and strong partnerships, Keros Therapeutics is poised to make significant contributions to the advancement of precision medicine.
Company Address: 1050 Waltham Street, Lexington, 2421 MA
Company Phone Number: 314-6297 Stock Exchange / Ticker: NASDAQ KROS
|
4.14% 